Philip Krause

For­mer FDA vac­cines deputy Krause heads down un­der as Mesoblast tries again on near­ly en­tire pipeline

Philip Krause will take his 11 years of in­sight from the up­per ech­e­lons of the FDA — es­pe­cial­ly dur­ing pan­dem­ic vac­cine nods — and ap­ply it to an Aus­tralian biotech that wants a sec­ond chance at se­cur­ing ap­proval in the US, par­tic­u­lar­ly as it looks to bounce back from a nixed No­var­tis deal.

The for­mer sec­ond-in-com­mand for vac­cines lead­er­ship at the FDA de­part­ed un­der murky cir­cum­stances last fall when he and Mar­i­on Gru­ber, di­rec­tor of the reg­u­la­tor’s Of­fice of Vac­cines Re­search & Re­view, re­port­ed­ly were miffed by the fed­er­al ad­min­is­tra­tion’s side­step­ping of the FDA on mat­ters of Covid-19 boost­er shots.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.